Neuroscience 2018 Scientific Posters

Charles River Poster Presentations

Neuroscience 2018 was a forum for Charles River scientists to showcase key findings from independent and collaborative research efforts with top scientists from across the globe. This year, Charles River scientists presented 26 scientific posters alone and with clients. The presentations are listed below.

Alzheimer's Disease

• Effects of antioxidant in mouse model for Alzheimer’s: a behavioral phenotyping and microdialysis study
  Marie Monbureau, Ayma F. Malik, Patrick J. Northey, Julien Roeser, Emily Holland, Claudio Ciardiello, Nadege Moristo, C. Zhu, Marieke van der Hart, Holden B. Janssens, Arash Rassoulpour
  Charles River, South San Francisco, CA
• Faster responding of Tg2576 mice in the touch screen version of the progressive ratio task
  Joni Järvenpää^1,2, Maksym V. Kopanitsa^1,3, Jukka Puoliväli^{1
  1}Charles River, Kuopio, Finland; ²University of Eastern Finland, Kuopio, Finland; ³UK Dementia Research Institute, Imperial College, London, UK

Multiple Sclerosis

• An oral gavage model for cuprizone-induced brain demyelination: Improved repeatability along with robust and specific phenotype
  Anna-Mari Kärkkäinen, Kimmo Lehtimäki, Anu Haapala, Teija Parkkari
  Charles River, Kuopio, Finland
• Neonatal hyperthyroidism induced developmental myelination model for multiple sclerosis
  Karen Lariosa-Willingham¹, Dmitri Leonoudakis¹, Diana Miszczuk²; Kimmo Lehtimäki², Laura Tolppanen², Megan Flanagan³, Janelle Gibson³, Antti Nurmi^{2
  1}Teva Pharmaceutical Industries, Redwood City, CA, USA; ²Charles River, Kuopio, Finland; ³Sword Diagnostics, Chicago, IL, USA
   

Parkinson's Disease

• Acquisition and reversal of visual discrimination learning in MPTP-treated C57BL/6J mice
  Joni Järvenpää1,^1,2, Maksym V. Kopanitsa1,^1,3, Artem Shatillo¹, Jussi Rytkonen¹, Lauri Remes¹, Jukka Puoliväli^{1
  1}Charles River Discovery, Kuopio, Finland; ²University of Eastern Finland, Kuopio, Finland; ³UK Dementia Research Institute, Imperial College, London, UK
• Assessment of the anti-parkinsonian effects of the potent and selective LRRK2 kinase inhibitor PF-360 in the AAV-A53T mouse model of Parkinson’s disease
  Robert Hodgson¹, Teija Parkkari¹, Terina Martinez², Matthew Fell³, Diane Bryce³, Taneli Heikkinen¹, Timo Bragge¹, Leena Tähtivaara¹, Miia Taavitsainen¹, James Koprich,⁵ Thomas Lanz⁴, Marco Baptista2
  ¹Charles River Discovery, Kuopio, Finland; ²The Michael J Fox Foundation, New York, NY, USA; ³Merck & Co. Inc., Boston, MA, USA; ⁴Pfizer Inc, Cambridge, MA, USA; ⁵Atuka Inc, Toronto, Canada
• Chronic treatment of LRRK2 inhibitors in diet produces an effect in the lung: Comparison of the effect in rats vs. mice
  Robert Hodgson¹, Teija Parkkari¹, Terina Martinez², Matthew Fell³, Diane Bryce³, Taneli Heikkinen¹, James Baily⁵, Alys Bradley⁵, Jussi Rytkönen¹, Miia Taavitsainen¹, James Koprich,⁶ Thomas Lanz⁴, Marco Baptista^{2
  1}Charles River Discovery, Kuopio, Finland; ²The Michael J Fox Foundation, New York, NY, USA; ³Merck & Co. Inc., Boston, MA, USA; ⁴Pfizer Inc, Cambridge, MA, USA; ⁵Charles River Discovery, Edinburgh, UK; ⁶Atuka Inc, Toronto, Canada
• Development and validation of a high content-based assay to measure Tom20 loss in dopaminergic human neurons differentiated
  Raymond de Wit¹, Folkert Verkaar¹, Marc Watson², Paul Thompson² and Sipke Dijkstra^{1
  1}Charles River Laboratories, Darwinweg 24, 2333 CR, Leiden, The Netherlands; ²Mission Therapeutics, Babraham Research Park, Moneta (Building 280), Cambridge, CB 22 3AT, UK
• Myricetin derivatives ameliorate deficits in 6-OHDA animal model of Parkinson's disease
  Daryl Thompson¹, Scott Truesdell¹, Maksym Kopanitsa²,³, Diana Miszczuk², Raimo Pussinen², William Durham⁴, Paula Miliani de Marval⁴, Timothy Jensen⁴, Gunnar Flik⁵, Eileen Seward⁶, Peter Crackett⁶, Paul Bury⁶, Daniel Small⁷, Antti Nurmi^{2
  1}GRDG Sciences, LLC, Winter Haven, FL, USA; ²Charles River Discovery, Kuopio, Finland; ³UK Dementia Research Institute, Imperial College, London, UK; ⁴Charles River Discovery, Morrisville, NC, USA; ⁵Charles River Discovery, Groningen, Netherlands; ⁶Charles River Discovery, Harlow, UK; ⁷Charles River Laboratories, Wilmington, MA, USA
• PR001 and PR002 modify motor phenotype in a rat model of Parkinson’s disease
  Lysimachos Zografos¹, J. Douglas Armstrong^{1, 2, 3}, R. Wayne Davies^1,2,3, Maksym Kopanitsa^4,5, Timo Bragge⁴, Leena Tähtivaara⁴, Robert Hodgson^{4
  1}Parkure Ltd, Edinburgh, UK; ²Brainwave Discovery Ltd, Edinburgh, UK; ³University of Edinburgh, School of Informatics, Edinburgh, UK; ⁴Charles River Discovery, Kuopio, Finland; ⁵UK Dementia Research Institute, Imperial College, London, UK

Psychiatry

• Does ketamine really modulate glutamate?
  Holden B. Janssens, Lisa Yu Harmen Kooijker, Bryson Cwick, Nadege Morisot, Julien Roeser, Marieke van der Hart, Arash Rassoulpour
  Charles River, South San Francisco, CA
• The development and utility of rodent paradigms to assess the activity of the vasopressin V1a receptor antagonists, balovaptan, and JNJ-17308616, in vivo
  Diana Miszczuk¹, Anna-Mari Kärkkäinen¹, Stuart Robjohns², Robert Hodgson^{1
  1}Charles River, Kuopio, Finland; ²Charles River, Saffron Walden, UK

Rare Disease

• Disease relevant in vitro assays for amytrophic lateral sclerosis in motor neurons derived from control and patient iPSCs
  S. Jain¹, M. BSIBSI¹, M. JANUS¹, J de Groot¹, D.F. Fischer²
• Fine motor performance, brain volumetry and metabolism in Cln2R207X/R207X nonsense point mutation model for CLN2 Batten disease
  Kimmo Lehtimäki¹, Timo Bragge¹, Jon Brudvig², Tyler Johnson², Derek Timm², Antti Nurmi¹, Jill Weimer², Jukka Puoliväli^{1
  1}Charles River, Kuopio, Finland; ²Sanford Research, Sioux Falls, SD, USA
• Longitudinal characterization of the Cln6nclf mouse model of CLN6 Batten disease — Characterization of fine motor performance, brain pathology and metabolic changes
  Kimmo Lehtimäki¹, Timo Bragge¹, Tuulia Huhtala¹, Maria Vihma¹, Jon Brudvig², Tyler Johnson², Derek Timm², Jukka Puoliväli¹, Jussi Rytkönen¹, Pekka Poutiainen³, Jill Weimer², Antti Nurmi^{1
  1}Charles River Discovery, Kuopio, Finland; ²Sanford Research, Sioux Falls, SD, USA; ³Kuopio University Hospital, Kuopio, Finland
• Principal component analysis (PCA)-based data fusion approach for a mouse model of CLN6 Batten disease
  Timo Bragge¹, Tuulia Huhtala¹, Jukka Puoliväli¹, Jon Brudvig², Tyler Johnson², Derek Timm², Jussi Rytkönen¹, Jill Weimer², Antti Nurmi,¹ Kimmo Lehtimäki^{1
  1}Charles River Discovery, Kuopio, Finland; ²Sanford Research, Sioux Falls, SD, USA

Stroke

• Functional imaging of thromboembolic stroke in rats using PET, ultrasound and MRI
  Jussi Rytkönen¹, Artem Shatillo¹, Elina Latonummi¹, Kimmo K. Lehtimäki¹, Pekka Poutiainen², Tuulia Huhtala¹, Diana Miszczuk¹, Antti Nurmi^{1
  1}Charles River Discovery, Kuopio, Finland; ²Kuopio University Hospital, Kuopio, Finland
• Quantitative susceptibility mapping (QSM) MRI in a collagenase rat model of intracerebral hemorrhage (ICH)
  Kimmo Lehtimäki, Artem Shatillo, Elina Latonummi, Antti Nurmi
  Charles River, Kuopio, Finland

Technology

• Functional ultrasound — Novel in vivo imaging technique for pre-clinical CNS drug discovery
  Artem Shatillo, Tuukka Miettinen, Juho Koponen, Anna-Mari Kärkkäinen, Diana Miszczuk, Antti Nurmi
  Charles River, Kuopio, Finland
• Translational PET imaging of neuroinflammation in pre-clinical rodent models of neurogenerative diseases
  Jussi Rytkönen¹, Pekka Poutiainen², Diana Miszczuk¹, Antti Nurmi¹, Tuulia Huhtala1
  ¹Charles River Discovery, Kuopio, Finland; ²Kuopio University Hospital, Kuopio, Finland
• Volumetric analysis of hexachlorophene-treated rats by MRM and stereology for neuropathology
  M. A. STAUP¹, D. BROWN¹, C. JOHNSON¹, P. LITTLE², R. SILLS³, G. A. JOHNSON⁴;
  ¹Pathology, Charles River, Durham, NC; ²Expt^l. Pathology Laboratories, Inc., Durham, NC; ³Cell. and Mol. Pathology for the Natl. Toxicology Program, Natl. Inst. of Envrn. Hlth. Sci., Durham, NC; ⁴Duke Ctr. for In Vivo Microscopy, Duke Univ., Durham, NC
   

Learn How We Can Support You Through The Entire Neuroscience Research Process